I have put this out before on the BMSN board. It's
Post# of 373
Posted On: 04/12/2015 5:24:33 PM
I have put this out before on the BMSN board. It's about BATU biologics, the private company co-founded by T. Ichim. I got great help understanding my concerns (and thank you- you know who you are) but I can not help but to revisit my contemplation again.
In the middle of march, Batu released a PR http://www.businesswire.com/news/home/2015031...SrcEpXn85u stating it is ready to submit an IND to FDA for ValloVax and attached its recently published work on the pre-clinical data supporting it. http://www.translational-medicine.com/content...0441-0.pdf
It is different than dCellVax but it's T. Ichims baby and also authored are Wei-ping Min, Amit Patel (who is actually going to be the lead investigator at Utah for trials) , and not an author here but on Batu's Scientific Advisory board is Boris Minev. Not concerned about Minev as he is a board member, however, I wish I knew if an investor should be concerned about this kind of cross-over with the others. "concern" is not the word I really want to use...just over-all puzzled on how this cross-over should be perceived and what it means for shareholders and how that relationship (sharing an employee who has competing work in 2 different companies and Amit who is researching for both companies) works...
Anyone have insight to relationships like these?
Batu has also done some hiring of recent, so they to are gearing up for growth. Impressive employees!
In the middle of march, Batu released a PR http://www.businesswire.com/news/home/2015031...SrcEpXn85u stating it is ready to submit an IND to FDA for ValloVax and attached its recently published work on the pre-clinical data supporting it. http://www.translational-medicine.com/content...0441-0.pdf
It is different than dCellVax but it's T. Ichims baby and also authored are Wei-ping Min, Amit Patel (who is actually going to be the lead investigator at Utah for trials) , and not an author here but on Batu's Scientific Advisory board is Boris Minev. Not concerned about Minev as he is a board member, however, I wish I knew if an investor should be concerned about this kind of cross-over with the others. "concern" is not the word I really want to use...just over-all puzzled on how this cross-over should be perceived and what it means for shareholders and how that relationship (sharing an employee who has competing work in 2 different companies and Amit who is researching for both companies) works...
Anyone have insight to relationships like these?
Batu has also done some hiring of recent, so they to are gearing up for growth. Impressive employees!
(0)
(0)